• PharmAla Biotech (MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo MDMA
  • PharmAla believes this is the largest single Health Canada export permit ever granted
  • Nicholas Kadysh, CEO of PharmAla, met with Sabrina Cuthbert to discuss the news
  • PharmAla (MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA
  • Pharmala Biotech Holdings Inc. (MDMA) opened trading at C$0.045

PharmAla Biotech (MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo MDMA.

PharmAla believes this is the largest single Health Canada export permit ever granted by weight to date.

Nicholas Kadysh, CEO of PharmAla, met with Sabrina Cuthbert to discuss the news.

“We’re incredibly proud of this milestone. It is additional proof that the clinical development of MDMA is moving forward. PharmAla exists to assist our client researchers around the world by not only saying we’ll provide them with research materials but actually delivering. The global psychedelics industry is still in its infancy, but strong demand for these molecules helps ensure a foundational role for manufacturers like PharmAla.”

PharmAla (MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX-class molecules, including MDMA.

Pharmala Biotech Holdings Inc. (MDMA) opened trading at C$0.045.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.

Fusion Pharmaceuticals shares soar 97% after AstraZeneca takeover

Fusion Pharmaceuticals' (NDAQ:FUSN) shares are up 97 percent after announcing it will be acquired by AstraZeneca for US$2.4 billion.